A Study of PRT3789 in Participants With Select Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers
About this trial
This is an interventional treatment trial for Advanced Solid Tumor focused on measuring Advanced Solid Tumors, BRG1, BRM, Metastatic Solid Tumors, Non-Small Cell Lung Cancers, NSCLC, PRT3789, SMARCA2 Degrader, SMARCA4
Eligibility Criteria
Inclusion Criteria: Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancy with loss of SMARCA4 due to truncating mutation and/or deletion by local testing that have either progress on or ineligible for standard of care therapy Must have measurable or non-measureable (but evaluable) disease Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Willing to provide either archival or fresh tumor tissue sample Adequate organ function (hematology, renal, and hepatic) Exclusion Criteria: Participants with solid tumors with known concomitant SMARCA2 mutation or loss of protein expression Clinically significant or uncontrolled cardiac disease, uncontrolled electrolyte disorders, uncontrolled or symptomatic central nervous system (CNS) metastases or leptomeningeal disease History of another malignancy within 3 years except for adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancies, or malignancies previously treated with curative intent and not on active therapy or expected to require treatment or recurrence during the study Concurrent treatment with strong or moderate CYP3A4 inhibitor or inducer
Sites / Locations
- University of California, Davis Comprehensive Cancer Center
- UCLA Hematology/Oncology - Santa MonicaRecruiting
- AdventHealth Medical Group Oncology Research at CelebrationRecruiting
- Massachusetts General HospitalRecruiting
- Dana Farber Cancer InstituteRecruiting
- Laura & Isaac Perlmutter Cancer Center at NYU Langone HealthRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- University Hospitals Cleveland Medical CenterRecruiting
- Cleveland ClinicRecruiting
- The University of Texas MD Anderson Cancer CenterRecruiting
- NEXT VirginiaRecruiting
- START MADRID - FJD Hospital Universitario Fundacion Jimenez DiazRecruiting
Arms of the Study
Arm 1
Experimental
PRT3789
PRT3789 will be administered by intravenous infusion